Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) INGELHEIM, Germany & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Boehringer Ingelheim  and  Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA...
View HTML
Toggle Summary Dicerna to Join NASDAQ Biotechnology Index
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 20, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the...
View HTML
Toggle Summary Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and...
View HTML
Toggle Summary Dicerna to Participate in Citi’s 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 29, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will host one-on-one...
View HTML
Toggle Summary Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018
Live Webcast to Begin at 8:30 a.m. Eastern Time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to discuss its...
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in...
View HTML
Toggle Summary Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019 Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna’s GalXC™ Technology Platform Closed $115.0 Million Financing...
View HTML
Toggle Summary Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 30, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on...
View HTML
Toggle Summary Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
- Companies will collaborate on RNAi research for cardio-metabolic, neurodegeneration and pain targets - Dicerna to receive an upfront payment of $100 million and an equity investment of $100 million - Dicerna eligible to receive up to approximately $350 million per target in development and...
View HTML
Toggle Summary Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)
Single-dose Data from Ongoing PHYOX Phase 1 Trial, Presented at ASN Kidney Week, Show Normalization or Near-normalization of Urinary Oxalate Levels in a Majority of Participants Reductions in Urinary Oxalate, Combined with Favorable Safety/Tolerability Profile, Lay Groundwork for Planned DCR-PHXC...
View HTML